Track Selecta Biosciences's long-term debt ($6.8M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), SELB shows a long-term debt of $6.8M. That compares with $9.6M in the prior-year period — down 28.8% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, SELB's long-term debt is now $6.8M (was $9.6M) — a 28.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Selecta Biosciences is outperforming or lagging.
Tracking SELB's long-term debt over time shows whether Selecta Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $6.8M That compares with $9.6M in the prior-year period — down 28.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Selecta Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $6.8M) with ownership activity and broader fundamentals.
Selecta Biosciences's long-term debt is $6.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.